The New Energy Crisis No One Saw Coming
Free investor report reveals how the electric car initiative is putting the U.S. in peril...and shows how to potentially capitalize on this crisis with a junior mining company.
See how this new energy crisis could create a boom
Franklin M. Berger net worth and biography

Franklin Berger Biography and Net Worth

Director of Rain Therapeutics
Franklin currently serves on the board of six public biotechnology companies: Five Prime Therapeutics (NASDAQ: FPRX), Bellus Health (NASDAQ: BLU), ESSA Pharma (NASDAQ: EPIX), Proteostasis (NASDAQ:PTI), Tocagen (NASDAQ: TOCA), and Kezar Life Sciences (NASDAQ:KZR). Previous public company board service includes eleven years with Seattle Genetics, seven years with VaxGen, (vaccines/biodefense) and Aurinia (previously Isotechnika), based in Canada. He also serves or has served on private biotech company boards including Atreca, Applied Therapeutics, Immune Design, (acquired by Merck in 2019), Rain Therapeutics, CERUS Endovascular, Caprion Proteomics, (sold in July 2012) and ViroChem Pharma, which was purchased by Vertex Pharmaceuticals, for $400 million in 2009. Franklin has led multiple M&A analyses resulting in >$3 billion in transaction value.

Franklin started his consulting practice in 2003 after leaving J. P. Morgan Securities, Inc. as head of biotechnology equity research. His clients were exclusively biotechnology industry participants including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies. Assignments included business development, strategic advisory/financings, partnering and royalty acquisitions. Some of his past mandates include Stemcentrx, PDL BioPharma, Inc., Intra-Cellular Therapeutics, Serono, Merck KGaA, Threshold Pharmaceuticals, Valeant (formerly Biovail), Kleiner Perkins Caufield & Byers.

As a senior portfolio manager on the buy-side, Franklin worked at Sectoral Asset Management as a co-founder of the small-cap focused NEMO Fund from 2007 through June 2008. He reduced his consulting practice commitment during his full time employment with Sectoral Asset Management.

Franklin spent twelve years in sell-side equity research, most recently as Managing Director, U.S. Equity Research, J. P. Morgan Securities, Inc., from May 1998 to March 2003. During his five years at J. P. Morgan Securities, Inc., he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities. Most of these transactions were lead-managed and book-run by the J. P. Morgan Biotech Team. He was associated with several notable financings in the biotechnology sector including the Genentech IPO, then the largest biotechnology IPO financing ever executed, the first large Celgene Corporation financings as well as several large-cap biotechnology companies in their rapid growth phase. His team covered 26 publicly-traded biotechnology companies. Franklin began his career as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst.

Institutional Investor Magazine ranked Franklin #3 on J. P. Morgan’s All-Star Research Team. The Wall Street Journal selected him as the No. 1 ranked biotechnology analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the WSJ’s 2000 Survey. In 2000, he became a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine.

Franklin received his MBA from Harvard Business School in 1975; Johns Hopkins University conferred both his MA and AB degrees in 1971 and 1972, respectively.

What is Franklin M. Berger's net worth?

The estimated net worth of Franklin M. Berger is at least $6.34 million as of November 21st, 2022. Mr. Berger owns 928,207 shares of Rain Therapeutics stock worth more than $6,339,654 as of December 6th. This net worth evaluation does not reflect any other investments that Mr. Berger may own. Learn More about Franklin M. Berger's net worth.

How do I contact Franklin M. Berger?

The corporate mailing address for Mr. Berger and other Rain Therapeutics executives is , , . Rain Therapeutics can also be reached via phone at 510-953-5559 and via email at [email protected] Learn More on Franklin M. Berger's contact information.

Has Franklin M. Berger been buying or selling shares of Rain Therapeutics?

During the last ninety days, Franklin M. Berger has bought $351,000.00 of Rain Therapeutics stock. Most recently, on Monday, November 21st, Franklin M. Berger bought 45,000 shares of Rain Therapeutics stock. The stock was acquired at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the transaction, the director now directly owns 928,207 shares of the company's stock, valued at $7,240,014.60. Learn More on Franklin M. Berger's trading history.

Are insiders buying or selling shares of Rain Therapeutics?

In the last year, Rain Therapeutics insiders bought shares 3 times. They purchased a total of 2,727,570 shares worth more than $15,990,383.10. The most recent insider tranaction occured on November, 21st when Director Franklin M Berger bought 45,000 shares worth more than $351,000.00. Insiders at Rain Therapeutics own 21.9 % of the company. Learn More about insider trades at Rain Therapeutics.

Information on this page was last updated on 11/21/2022.

Franklin M. Berger Insider Trading History at Rain Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2022Buy45,000$7.80$351,000.00928,207View SEC Filing Icon  
9/21/2021Buy3,786$14.30$54,139.80View SEC Filing Icon  
See Full Table

Franklin M. Berger Buying and Selling Activity at Rain Therapeutics

This chart shows Franklin M Berger's buying and selling at Rain Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rain Therapeutics Company Overview

Rain Therapeutics logo
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Read More

Today's Range

Now: $6.82
Low: $6.45
High: $7.33

50 Day Range

MA: $5.98
Low: $3.94
High: $8.48

2 Week Range

Now: $6.82
Low: $2.15
High: $14.49


869 shs

Average Volume

111,052 shs

Market Capitalization

$181.21 million

P/E Ratio


Dividend Yield



The New Energy Crisis No One Saw Coming
Free investor report reveals how the electric car initiative is putting the U.S. in peril...and shows how to potentially capitalize on this crisis with a junior mining company.
See how this new energy crisis could create a boom